XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)
3 Months Ended 9 Months Ended
Oct. 03, 2018
USD ($)
obligation
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Sep. 30, 2021
USD ($)
May 31, 2021
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenues   $ 32,412,000 $ 45,891,000 $ 211,656,000 $ 100,004,000    
Deferred revenue   84,288,000   84,288,000   $ 111,055,000  
Collaboration and License agreements              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Initial transaction price $ 252,700,000            
JJDC | Common Stock Purchase Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Proceeds from the issuance of common stock 75,000,000            
Janssen | Collaboration and License agreements              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Cash received as due under collaboration agreement 175,000,000            
Janssen              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Milestone payment 73,000,000            
Development, regulatory and sales milestones payments   4,900,000,000   4,900,000,000      
Janssen | License Agreement | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Development, regulatory and sales milestones payments 1,600,000,000            
Janssen | Collaboration Agreement | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Development, regulatory and sales milestones payments 600,000,000            
Janssen | JNJ-3989 (ARO-HBV) Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Milestone payment $ 25,000,000            
Number of distinct performance obligations | obligation 1            
Revenues   0 0 0 20,200,000    
Contract assets   0   0      
Deferred revenue   0   0      
Janssen | JNJ-75220795 (ARO-JNJ1)              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Milestone payment     10,000,000   10,000,000   $ 10,000,000
Revenues   0 $ 200,000 100,000 $ 500,000    
Contract assets   0   0      
Deferred revenue   $ 0   $ 0